News | November 14, 2024
AstraZeneca invests US$ 3.5 billion in R&D and manufacturing in US
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
The new facility uses the latest mammalian systems and single-use technology, including a production line with eight 2,000 L bioreactors
The GMP certificate will allow the manufacturing site in Hervás, Cáceres to manufacture active ingredients for the pharmaceutical industry that is based on medicinal plants
This product is categorized as antacids, antiflatulents and anti-Ulcerants
Subscribe To Our Newsletter & Stay Updated
